European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Go back to European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status| Gilead Sciences (NASDAQ: GILD) | Delayed: 146.64 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $146.64 | 52 Week High | $108.63 | |||
| Open | $146.64 | 52 Week Low | $71.39 | |||
| Day High | $146.64 | P/E | 81.02 | |||
| Day Low | $146.64 | EPS | $1.81 | |||
| Volume | 593 | |||||
